Brain metastasis is common and carries a poor prognosis in melanoma. A single institution, retrospective cohort of 225 melanoma patients was analyzed to determine if BRAF-V600 mutational status was associated with brain metastasis. Eighty-three of the 225 patients (37%) had BRAF-V600 mutations. At initial diagnosis, BRAF-V600 mutations were associated with younger age (p 0.001), higher proportion of females (p 5 0.0037), higher AJCC stage (p 5 0.030), regional lymph node involvement (p 5 0.047), and family history of cancer (p 5 0.044). Compared to BRAF-WT, BRAF-V600 patients had an increased risk of brain metastasis in multivariate analysis (OR 5 2.24; 95% CL 5 1.10-4.58; p 5 0.027). However, BRAF-V600 patients treated with a selective BRAF inhibitor (BRAFi) had a similar risk of brain metastasis compared to BRAF-WT patients (OR 5 1.00; 95% CL 5 0.37-2.65; p 5 0.98). Moreover, treatment with BRAFi significantly prolonged the time from initial diagnosis to brain metastasis diagnosis (HR 5 0.30; 95% CL 5 0.11-0.79; p 5 0.015). Compared to other tissues, the brain was the most frequent site of metastasis in BRAF-V600 patients without BRAFi (42% 6 7%). The frequency of brain metastasis was lower in BRAF-WT and BRAF-V600 patients with BRAFi (25% 6 4% and 25% 6 8%, respectively). The proportion of patients with brain metastasis as the only site was 40%, 60%, and 0% in the BRAF-WT, BRAF-V600 without BRAFi, and BRAF-V600 with BRAFi groups, respectively. This study provides evidence on the clinical importance of BRAF-V600 mutations and BRAF inhibition in the progression to melanoma brain metastasis. presents as multiple lesions, displays radio-resistance, and has a high tendency for hemorrhage. 10,11 Thus, it is important to identify melanoma patients at an increased risk of brain metastasis and to find ways to prevent brain metastasis and subsequent complications. BRAF (v-raf murine sarcoma viral oncogene homolog B1) is a serine/threonine kinase and involved in the RAS-RAF-MEK-MAPK signaling pathway, which regulates cell proliferation, differentiation, senescence, and apoptosis/survival.
The incidence of melanoma continues to rise worldwide. 1 Melanoma is a frequent cause of brain metastasis. 2, 3 Brain metastasis is diagnosed in 7-10% of all melanoma patients regardless of tumor stage and in 44-50% of patients with stage IV disease. [3] [4] [5] [6] Moreover, up to 75% of melanoma patients have brain metastasis detected on autopsy. 7 Melanoma brain metastasis is a poor prognostic factor that indicates a median overall survival of 5 months from detection. 8 Furthermore, there are significant limitations in the treatment and management of melanoma brain metastasis despite recent advancements. 9 Melanoma brain metastasis often presents as multiple lesions, displays radio-resistance, and has a high tendency for hemorrhage. 10, 11 Thus, it is important to identify melanoma patients at an increased risk of brain metastasis and to find ways to prevent brain metastasis and subsequent complications. BRAF (v-raf murine sarcoma viral oncogene homolog B1) is a serine/threonine kinase and involved in the RAS-RAF-MEK-MAPK signaling pathway, which regulates cell proliferation, differentiation, senescence, and apoptosis/survival. 12 Somatic BRAF mutations are present in 34-41% of melanoma tumors. [13] [14] [15] The most common and well-characterized BRAF mutation is the substitution of codon 600 (BRAF-V600). This and other mutations have been shown to constitutively activate the RAS-RAF-MEK-MAPK signaling pathway. 13, 16, 17 Preclinical and clinical studies have shown that this aberrant signaling is associated with uncontrolled proliferation, inhibition of apoptosis, immune evasion, and disease progression of melanoma. 16, [18] [19] [20] [21] [22] For these reasons, selective inhibitors of mutated BRAF (BRAFi), vemurafenib, and dabrafenib, have been developed and have improved the progression-free and overall survival of melanoma patients with BRAF-V600 mutations. 23, 24 Combination with MEK inhibitors further enhances overall survival through a mechanism thought to decrease the resistance of melanoma to BRAFi. 25, 26 Vemurafenib has also shown non-small-cell lung cancer, Erdheim-Chester disease, and Langerhans'-cell histiocytosis harboring BRAF-V600 mutations. 27 Given melanoma's high propensity to metastasize to the brain, the present study sought to determine whether BRAF-V600 mutational status plays a role in the development of brain metastasis. A retrospective cohort of 225 melanoma patients treated at a single institution was analyzed to explore this question. We hypothesized melanoma patients with BRAF-V600 mutations have an increased risk of brain metastasis compared to BRAF wild type (BRAF-WT) patients. In addition, we investigated whether there is evidence that treatment with BRAFi may therefore reverse this increased risk and delay the progression to brain metastasis in those with BRAF-V600 mutations.
Material and Methods

Patient selection and clinical data collection
Under an Institution Review Board-approved protocol, we identified a retrospective cohort of 225 melanoma patients from the Johns Hopkins Hospital (JHH) Cancer Registry who underwent molecular testing for BRAF mutations performed by the JHH Molecular Diagnostics Laboratory. These melanoma patients presented to JHH from April 2000 to January 2014 for the treatment of primary or recurrent disease.
Data on patient demographics (age at diagnosis, sex, and family history of cancer), clinico-pathologic characteristics of primary disease (anatomical site, laterality, histological subtype, American Joint Committee on Cancer [AJCC] stage, regional lymph node involvement, Breslow thickness, ulceration, mitotic rate, and serum lactate dehydrogenase [LDH]), clinical management, and outcomes of interest were collected from both the JHH Cancer Registry database and electronic medical records. Primary outcome measures included the presence of brain metastasis and brain metastasis (BM)-free survival, defined as the time from initial melanoma diagnosis to radiological diagnosis of brain metastasis. Routine screening for brain metastasis was not performed in this retrospective cohort. Brain metastasis diagnosis was established as the date when brain metastasis was first found on either brain computed tomography or magnetic resonance imaging. Secondary outcome measures included the presence of other tissue metastatic sites before last day of follow-up. Systemic treatments either before brain metastasis diagnosis or last day of follow-up in patients without brain metastasis with chemotherapy, immunotherapy, and/or BRAFi treatment were also recorded.
BRAF mutation testing
Results of BRAF-V600 mutational status for each patient were obtained from records of the JHH Molecular Diagnostics Laboratory of the Division of Pathology. BRAF mutational testing was performed on formalin-fixed, paraffinembedded tissue from unrecorded diagnostic and/or therapeutic procedures. Extracted DNA from tissue sections was analyzed using two different polymerase chain reaction (PCR)-based methods due to a change in methodology in the department in 2013. Tissue from 161 patients (72%) was analyzed for mutations by pyrosequencing in BRAF codons 597-601 of exon 15. Tissue samples from 64 patients (28%) were analyzed using next-generation sequencing (NGS) for mutations in BRAF as well as NRAS, KRAS, EGFR, PIK3CA, and KIT. For the interests of this study, both PCR methods were included because they both are able to detect BRAF-V600 mutations. To adjust for the differences in the methodologies, patients with BRAF mutations outside codon 600 were analyzed in the BRAF-WT group. Compared to BRAF-V600 mutations, less is known about the functional and clinical relevance of these other BRAF mutations.
Statistical analysis
Patient demographics and clinico-pathologic characteristics of primary disease were analyzed to determine associations with BRAF-V600 mutational status and the presence of brain metastasis. Categorical variables were summarized using counts and proportions and compared across groups using Fisher's exact test. Continuous variables were summarized using medians and ranges and compared across groups using the Mann-Whitney U test. Univariate and multivariate binary logistic regression models were constructed to calculate odds ratios and 95% confidence limits (CLs) for predictors of brain metastasis development. Univariate and multivariate analyses with Cox proportional hazards regression models were also used to measure associations for BM-free survival. The characteristics found to be statistically significant associates with brain metastasis were analyzed as covariates in the regression models. Patients with unknown covariate information were analyzed as a subgroup in regression models in What's new? When melanoma spreads to the brain, it usually kills the patient inside a year. How can these metastases be predicted and stopped before they become lethal? These authors investigated whether a mutation in the BRAF gene increases the chances of brain metastasis. From a cohort of 225 melanoma patients, they showed that those carrying a mutation at BRAF-V600 developed brain metastases more often than those with normal copies of the gene. When patients with the BRAF-V600 mutation received treatment with BRAF inhibitor, however, the effect was reversed, and patients experienced the same risk as those without BRAF mutations.
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order to increase the power of the statistical tests. KaplanMeier plots using the log-rank test were used to analyze BMfree survival for the patients who developed brain metastasis. To compare the presence of other metastatic tissue sites between groups, proportions with standard errors were calculated and analyzed using Fisher's exact test. All analyses were considered statistically significant if two-tailed p values were less than a type I error rate set at 0.05. All statistical analyses were carried out using SAS software, version 9.2 (SAS Institute, Cary, NC).
Results
Associations between patient demographics and Clinico-pathologic characteristics of primary disease according to BRAF-V600 mutational status
As shown in Table 1 , out of the 225 identified melanoma patients who underwent BRAF mutational testing, BRAF-V600 mutations were detected in 83 patients (37%). Sixtyfour of these patients had their BRAF-V600 mutations detected by pyrosequencing (40% of the 161 patients with pyrosequencing data), and 19 had their mutations detected by NGS (30% of the 64 patients with NGS data). There was not a significant difference in the BRAF-V600 mutation detection rate between the two PCR methods (p 5 0.17). Of the 83 patients with detected BRAF-V600 mutations, 70 (84%) had V600E mutations; 10 (12%) had V600K mutations; 2 (3%) had V600R mutations; and 1 (1%) had an unknown V600 mutation recorded. BRAFi treatment was used in 28 of the 83 patients (34%) with BRAF-V600 mutations (14 only on a single agent and 14 on single agent plus MEK inhibitor). One hundred and forty-two patients (63%) were analyzed in the BRAF-WT group. The majority of these patients had no detected BRAF mutations (n 5 134; 94%; 96 using pyrosequencing and 38 using NGS). Eight of these patients (6%; 1 using pyrosequencing and 7 using NGS) had BRAF mutations detected outside codon 600. These genotypes included 2 K601E substitutions, L597R, D594N, L584F, G469V, S467L, and G466A. Because less is known about the functional and clinical significance of these uncommon non-V600 BRAF mutations, these patients were analyzed within the BRAF-WT group.
Sixty-four of the 225 patients (28%) had available NGS data for detecting mutations within other genes including NRAS, KRAS, EGFR, PIK3CA, and KIT. Of those with BRAF-V600 mutations (n 5 19; 30%), there were no concurrent NRAS or other gene mutations detected. Of those with BRAF-WT mutational status (n 5 45; 70%), there were 21 NRAS, 1 KRAS, 1 EGFR, 2 PIK3CA, and 1 KIT mutations detected. Of note, the majority of the 225 patients (n 5 161; 72%) had pyrosequencing data for only BRAF mutations in codons 597-601 of exon 15; therefore, the mutational status of other genes was unknown for these patients.
Patient demographics and clinico-pathologic characteristics of primary disease according to BRAF-V600 mutational status are listed in Table 1 . Patients with BRAF-V600 mutations were significantly younger than BRAF-WT patients at primary melanoma diagnosis (median age, 53.0 versus 59.5 years; p 0.001). The proportion of females was significantly higher in those with BRAF-V600 mutations (47%) compared to BRAF-WT patients (27%) (p 5 0.0037). When comparing clinico-pathologic characteristics of primary disease, BRAF-V600 mutational status was associated with a higher AJCC stage (p 5 0.037) and regional lymph node involvement (p 5 0.047). There was also a significantly higher proportion of a positive family history of cancer in the BRAF-V600 group compared to the BRAF-WT Group (73% versus 61%; p 5 0.044). All other characteristics (anatomical site, laterality, histological subtype, Breslow thickness, ulceration, mitotic rate, and serum LDH) were not significantly different between the BRAF-V600 and BRAF-WT groups.
Associations with brain metastasis
Patient demographics, clinico-pathologic characteristics of primary disease, and use of systemic treatments before brain metastasis diagnosis were tested for associations with the presence of brain metastasis ( Table 2 ). In this retrospective cohort of 225 patients, 65 (29%) were found to have a brain metastasis diagnosis during their clinical course. Brain metastasis was found to be significantly associated with a higher AJCC stage at primary diagnosis (p 5 0.0097). Patients with brain metastasis were more likely to have stage IV disease at primary diagnosis compared to patients without brain metastasis (25% vs. 13%). Brain metastasis was also associated with the lack of temozolomide treatment (p 5 0.028). Patients without brain metastasis were more likely to have temozolomide treatment compared to patients with brain metastasis (20% vs. 8%). There were no significant differences found between those with and without brain metastasis in other characteristics (age at primary diagnosis, sex, anatomical site, laterality, histological subtype, regional lymph node involvement, Breslow thickness, ulceration, mitotic rate and serum LDH). Also, the use of systemic treatments with BRAFi, immunotherapy or other non-temozolomide chemotherapy before brain metastasis diagnosis was not significantly different between those with and without brain metastasis.
Effects of BRAF-V600 mutational status and BRAFi treatment on brain metastasis development
Regression models were constructed to determine if BRAF-V600 mutational status was an independent predictor of development of brain metastasis in the 225 patients. AJCC stage at primary diagnosis and temozolomide use were analyzed in the regression models since both were found to be significant associates with brain metastasis (p 5 0.0097 and p 5 0.028, respectively). Those with an unknown AJCC stage (n 5 55; 24%) were included as a subgroup in the analyses. BRAFi treatment improves the survival of melanoma patients with BRAF-V600 mutated tumors. [23] [24] [25] [26] Thus, patients in the BRAF-V600 group were further subcategorized according to treatment with BRAFi before brain metastasis diagnosis. This 
BM-free survival according to BRAF-V600 mutational status and BRAFi treatment
The median BM-free survival was 2.6 years for the 65 patients who developed brain metastasis. The BM-free survivals in the BRAF-WT, BRAF-V600 without BRAFi, and BRAF-V600 with BRAFi groups were 2.5, 2.6 and 3.2 years, respectively. Cox proportional regression models accounting for AJCC stage at primary diagnosis and temozolomide use were constructed to further evaluate BM-free survival in these patients ( Table 4 ). The BRAF-V600 patients treated without a BRAFi were not found to have a significantly different BMfree survival compared to BRAF-WT patients 1 Patients with unknown characteristics were excluded from statistical analyses. Categorical variables were analyzed using Fisher's exact test. Continuous variables were analyzed using the Mann-Whitney U test. 2 Only single agent (n 5 14) and single agent plus MEK inhibitor (n 5 14). 3 Spindle cell (n 5 5), lentigo maligna (n 5 4), desmoplastic (n 5 2), melanoma in situ (n 5 2) and epithelioid cell morphology (n 5 1). 4 1 Patients with unknown characteristics were excluded from statistical analyses. Categorical variables were analyzed using Fisher's exact test. Continuous variables were analyzed using the Mann-Whitney U test. 2 Only single agent (n 5 14) and single agent plus MEK inhibitor (n 5 14). 3 Only interferon-alpha (n 5 11), interleukin-2 (n 5 12), tumor peptide vaccine (n 5 6), ipilimumab (n 5 27), nivolumab (n 5 1), and combinational/multiple immunotherapy regimen (n 5 62). 4 Only dacarbazine (n 5 3), carboplatin (n 5 1), paclitaxel (n 5 1), sorafenib (n 5 1), multiple chemotherapy regimens (n 5 16), and unknown agent(s) (n 5 
Other metastatic tissue sites
One hundred and fifty-six of the 225 patients (69%) were found to develop distant metastases during their clinical course. The most frequent site of metastases in the cohort was the lungs (35%) followed by the brain (29%), lymph nodes (23%), other soft tissue sites (18%), liver (16%) and bone (12%). Thirteen patients (6%) had unspecified, extracranial metastases involving multiple sites. Figure 2a shows the frequencies with standard error bars of different metastatic tissue sites in the BRAF-WT, BRAF-V600 without BRAFi, and BRAF-V600 with BRAFi groups. In BRAF-V600 patients without BRAFi, the most frequent site of metastases was the brain (42% 6 7%) followed by lymph nodes (33% 6 6%) and lungs (27% 6 6%). This profile of metastatic tissue sites was different for the patients who were BRAF-WT or BRAF-V600 with BRAFi treatment. For BRAF-WT patients, the most frequent sites of metastases were the lungs (36% 6 4%) followed by the brain (25% 6 4%). Similarly, the lungs (43% 6 10%) and brain (25% 6 8%) were the top most frequent sites in BRAF-V600 patients with BRAFi treatment. Despite this trend, no statistically significant difference could be shown in the metastatic site frequencies between the three groups using Fisher's exact test. Next, the patterns of tissue-specific metastases were compared between the three groups in order to determine if brain metastasis was a BRAF-V600 specific event or a byproduct of progressive disease with multiple tissue involvement. This was tested by analyzing the 156 patients with distant metastases on a theoretical spectrum of increasing selective brain involvement, i.e. those with only extracranial metastases to brain metastasis plus 2 extracranial sites to brain metastasis plus 1 extracranial site to patients with only brain metastasis. Figure 2b shows the proportions of the three groups along this spectrum. BRAF-WT patients were found to represent the majority of those with only extracranial metastases and brain metastasis plus 2 extracranial sites (68% and 69%, respectively). For the BRAF-V600 patients without BRAFi, there was a trend towards an increase in selective brain involvement in metastatic disease (19% to 26% to 40% to 60% in patients with only extracranial metastases, brain metastasis plus 2 extracranial sites, brain metastasis plus 1 extracranial site, and only brain metastasis, respectively). Those with BRAF-V600 with BRAFi had a modest trend of increasing selective brain involvement (13% to 6% to 25% in patients with only extracranial metastases, brain metastasis plus 2 extracranial sites, and brain metastasis plus 1 extracranial site, respectively). However, these patients had no representation in the only brain metastasis group. The proportions within the brain metastasis plus 1 extracranial site were only found to be significantly different between the three groups using Fisher's exact test (p 5 0.015).
Discussion
Development of brain metastasis in melanoma carries a poor prognosis, but therapy with BRAFi has been demonstrated to improve survival outcome in patients with advanced disease. [23] [24] [25] [26] The benefit of BRAFi for patients with brain metastasis is unknown. The identification of melanoma patients at an increased risk of brain metastasis is important for proper management. In this retrospective study, a large cohort of 225 melanoma patients treated at a single institution was analyzed to determine whether BRAF-V600 mutational status plays a role in the development of brain metastasis. Results of this study suggest BRAF-V600 mutational status without selective inhibition is an independent predictor of brain metastasis in melanoma patients. Furthermore, inhibition of mutated BRAF appears to abrogate this effect by prolonging BM-free survival when accounting for AJCC stage at primary diagnosis and temozolomide treatment. This study also found AJCC stage at primary diagnosis to be an independent predictor of brain metastasis and BM-free survival, which has been previously shown. 28 This study provides further evidence on the clinical relevance of BRAF mutations in the development of brain metastasis. In a Cancer Genetics and Epigenetics large retrospective cohort, melanoma patients with either BRAF or NRAS mutations were more likely to have central nervous system involvement at stage IV diagnosis (p 5 0.0076). 29 In a study evaluating BRAF-V600E expression in melanoma brain metastasis, 55% of brain metastasis showed homogeneous staining by immunohistochemistry. 30 In the present study, BRAF-V600 positive patients without BRAFi treatment had significantly higher risk of brain metastasis but experienced no difference in BM-free survival compared to BRAF-WT patients. Similarly, in a review of 80 patients with advanced cancers including melanoma, it was shown that patients with mutated BRAF tumors had increased odds of brain metastasis compared to a control BRAF-WT group (OR 5 2.05; 95% CL 5 1.02-4.11; p 5 0.043). 31 There is little information regarding the role of different BRAF mutations on the prognosis of patients with melanoma. It has been observed that melanoma patients with BRAF-V600K mutations had more frequent brain metastasis as well as a shorter overall survival (OS) compared to other BRAF mutations. 31 Similarly, another study found that stage IV melanoma patients with BRAF-V600K had a shorter OS compared to BRAF-V600E patients. 32 These results suggest that different mutations within the same oncogene can lead to different clinical outcomes including brain metastasis development. Although BRAF-V600E and BRAF-V600K have been shown to lead to constitutive activation of the RAS-RAF-MEK-MAPK pathway, there could possibly be unfound aberrant functions of BRAF-V600K and other mutations. 16 Aside from mutational differences within BRAF, other gene mutations also appear to play an important role in brain metastasis. For instance, loss of PTEN expression in BRAF-V600 mutated tumors was found to be associated with a 
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BRAF and melanoma brain metastasis is a controversial topic in the literature. Some studies have shown that BRAF mutations have no impact on the development of brain metastasis in melanoma. [34] [35] [36] When analyzing these studies, including the present, results should be viewed taking into account differences in methodologies, study populations, and inherent biases. In a German cohort of 215 stage IV melanoma patients who underwent systemic treatment with either dacarbazine or temozolomide, BRAF-V600 mutational status was not found to be associated with brain metastasis development (p 5 0.307). 35 Because of its ability to cross the bloodbrain barrier, temozolomide is a well-established alkylating agent used to treat brain metastases and primary brain tumors. 37, 38 In the German cohort, temozolomide was used in a significant proportion of the BRAF-V600 positive patients (44%), which could have confounded the study's results. A likely hypothetical mechanism is that temozolomide within the BRAF-V600 group was treating brain micrometastases that could not develop into clinically apparent brain metastasis. Despite low response rates in melanoma, temozolomide regimens have been found to decrease the occurrence of melanoma brain metastasis in certain studies, while others suggest otherwise. [39] [40] [41] The current study supports the former notion since temozolomide use was associated with a lower risk of brain metastasis within this retrospective cohort. Temozolomide use also prolonged BMfree survival, but this result was not found to be statistically significant.
Another recent study found similar incidences of brain metastasis between melanoma patients with BRAF mutations versus those without (incidence rate ratio 5 1.11; 95% CL 5 0.80-1.53; p 5 0.53). 36 However, this study did not account for the protective effects of BRAFi treatment on brain metastasis. Out of the patients with BRAF mutations, the majority (76%) were treated with vemurafenib. The investigators observed a lower incidence rate of brain metastasis in these patients compared to those who were not treated with vemurafenib (incidence rate ratio 5 0.51; 95% CL 5 0.30-0.86; p 5 0.009). Similarly, in the present study, BRAF-V600 patients treated with a BRAFi experienced a longer BM-free survival compared to BRAF-WT patients after adjusting for AJCC stage at primary diagnosis and temozolomide use. BRAFi treatment could protect against brain metastasis by controlling systemic disease or treating brain micrometastases. The latter is plausible given that both dabrafenib and vemurafenib have shown intracranial responses in melanoma patients with brain metastasis. [42] [43] [44] In a multicenter phase 2 trial, dabrafenib was able to achieve >30% overall intracranial response rates in melanoma patients who either were treatment na€ ıve for their brain metastasis or had progressive brain disease. 44 In a pilot study of 24 melanoma patients with symptomatic brain metastasis, vemurafenib achieved an overall partial response rate of 42% in both intracranial and extracranial sites as well as stable disease in 38% of the patients. 42 Further work is needed to explore the benefits and combined effects of BRAF inhibition and stereotactic radiosurgery in melanoma brain metastasis. 45 The present study also compared brain metastasis with other extracranial metastatic tissue sites in the BRAF-WT, BRAF-V600 without BRAFi, and BRAF-V600 with BRAFi groups. Shoenewolf et al. examined 83 stage IV melanoma patients and found similar patterns of metastases between BRAF-V600E and BRAF-WT patients. 46 In the present cohort, the brain was the most frequent metastatic tissue site in the BRAF-V600 without BRAFi treatment (42% 6 7%). The lungs (36% 6 4%) followed by the brain (25 %6 4%) were the most frequent metastatic tissue sites in BRAF-WT patients. Interestingly, BRAF-V600 patients with BRAFi treatment showed a similar pattern with the lungs (43% 6 10%) and then the brain (25% 6 8%) being the most frequent sites. Along with being the most frequent site, the brain also appeared to be a selective site of metastases in the BRAF-V600 without BRAFi group. These patients showed an increasing trend in selective brain involvement in metastatic disease (19% to 26% to 40% to 60% in patients with only extracranial metastases, brain metastasis plus 2 extracranial sites, brain metastasis plus 1 extracranial site, and only brain metastasis, respectively). The BRAF-WT and BRAF-V600 with BRAFi did not show this clear trend. These results suggest that BRAF-V600 mutated tumors may have a certain affinity for the brain versus other metastatic tissue sites. BRAF-V600 mutated tumors could possibly have a growth advantage or a more favorable tumor microenvironment in the brain compared to BRAF-WT tumors. Notably, BRAF mutations including gene fusions are found at high frequencies in primary brain tumors. 47, 48 This study is limited in that it is a single center experience and by its retrospective nature, which impacted the quality and availability of data for the entire cohort. There is inherent selection bias given that the information analyzed belonged only to patients who underwent BRAF mutational testing and who also had data within the JHH Cancer Registry. However, it is important to note that many of the study population's characteristics according to BRAF-V600 mutational status are consistent with other studies. The frequency of BRAF-V600 mutations in this study population (37%) is within the range found in meta-analysis data (34-41%). 14, 15 Similar to other studies, BRAF-V600 mutational status was associated with younger age at primary diagnosis (p 0.001) and higher proportion of females (p 5 0.0037). 21, 31, 34 AJCC stage at diagnosis (p 5 0.030), regional lymph node involvement (p 5 0.047), and any family history of cancer (p 5 0.044) were also found to be significantly associated with BRAF-V600 mutational status in this study. The division of BRAF-V600 patients into those who did or did not receive BRAFi treatment may also be inherently biased because BRAF-V600 patients with early brain metastasis diagnosis may not have had a chance to begin BRAFi treatment. Other drawbacks include the lack of routine screening for brain metastasis, the nonuniform screening methods for BRAF mutations, treatment heterogeneity, and small sample sizes within some of the sub-group analyzes. Also, BRAF mutational status in the brain metastatic lesions was unknown. There is some evidence of intertumoral homogeneity of BRAF-V600E immunostaining between the melanoma primary and metastatic sites. 49, 50 However, it is uncertain if this applies to brain metastasis, and it would be interesting to determine if there is any discordance in BRAF-V600 testing between the primary and brain metastasis tumors. Future investigations are warranted to determine whether BRAF-WT tumors give rise to BRAF-V600 positive tumors of brain metastasis.
In conclusion, BRAF-V600 mutational status appears to be an independent predictor of brain metastasis in this retrospective cohort of melanoma patients. This finding is further supported because inhibition with BRAFi reversed the increased risk of brain metastasis as well as delayed brain metastasis diagnosis in BRAF-V600 positive patients. Patients with selective brain metastasis also had BRAF-V600 positive tumors. This study should be considered exploratory, and continuing investigation is warranted to provide further evidence on the clinical relevance of BRAF and melanoma brain metastasis. Thus, the findings from this single institution study must be validated with preclinical models, other institutional cohorts, and properly designed prospective studies. Nonetheless, this study suggests BRAF-V600 mutational status may play an important role in the natural course of melanoma brain metastasis. BRAFi treatment may prove to be a rational strategy in preventing melanoma brain metastasis and its dismal complications.
